A comparative study on nivolumab and axitinib as secondary treatment in patients with metastatic renal cell carcinoma: A multi-institutional retrospective study in Japan.

Taigo Kato,Satoru Yumiba,Wataru Nakata,Kosuke Nakano,Akira Nagahara,Kyosuke Matsuzaki,Yujiro Hayashi,Koji Hatano,Atsunari Kawashima,Tetsuya Takao,Kensaku Nishimura,Yasutomo Nakai,Masashi Nakayama,Kazuo Nishimura,Shingo Takada,Masao Tsujihata,Motohide Uemura,Norio Nonomura,Ryoichi Imamura

International journal of urology : official journal of the Japanese Urological Association（2022）

引用 1|浏览14

暂无评分

摘要

Nivolumab and axitinib showed similar clinical benefits as secondary treatment in patients with mRCC; thus, they should be an option in sequential therapy following treatment with tyrosine kinase inhibitors (TKIs). Future studies and feasible therapeutic biomarkers would help predict the clinical response to TKIs or immune checkpoint inhibitors in patients with mRCC.

查看译文

关键词

axitinib,nivolumab,renal cell carcinoma

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要